We are live on ! Find out more
RP

Riverbridge Partners Portfolio holdings

AUM $3.58B
1-Year Est. Return 4.02%
This Fund
S&P 500
This Quarter Est. Return
+8.82%
1 Year Est. Return
+4.02%
3 Year Est. Return
+40.43%
5 Year Est. Return
+44.7%
10 Year Est. Return
+473.33%
AUM
$5.23B
AUM Growth
+$250M
Cap. Flow
-$112M
Cap. Flow %
-2.15%
Top 10 Hldgs %
28.91%
Holding
145
New
10
Increased
12
Reduced
104
Closed
6

Top Buys

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$55.9M
2
WST icon
West Pharmaceutical
WST
+$47M
3
ALRM icon
Alarm.com
ALRM
+$45.3M
4
GLOB icon
Globant
GLOB
+$38.4M
5
ADI icon
Analog Devices
ADI
+$24.6M

Top Sells

Rank Stock Value
1
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$70.1M
2
CGNX icon
Cognex
CGNX
+$62.5M
3
SRCL
Stericycle Inc
SRCL
+$42.1M
4
VEEV icon
Veeva Systems
VEEV
+$25.1M
5
NEOG icon
Neogen
NEOG
+$24.7M

Sector Composition

Rank Sector Weight
1 Technology 26.74%
2 Industrials 21.8%
3 Healthcare 18.73%
4 Consumer Discretionary 10.85%
5 Consumer Staples 6.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ORCL icon
126
Oracle
ORCL
$374B
$251K ﹤0.01%
5,000
FDX icon
127
FedEx
FDX
$72.7B
-1,228
Closed -$240K
NEE icon
128
NextEra Energy
NEE
$181B
-7,568
Closed -$243K
VXF icon
129
Vanguard Extended Market ETF
VXF
$30.3B
-11,408
Closed -$1.14M
XOM icon
130
ExxonMobil
XOM
$644B
-2,745
Closed -$225K
VAL
131
DELISTED
Valspar
VAL
-2,441
Closed -$271K
ZLTQ
132
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
-1,260,664
Closed -$70.1M

Similar funds

Riverbridge Partners's Q2 2017 Portfolio in Review

As of Q2 2017, Riverbridge Partners held 145 positions worth $5.23B, up 5% from $4.98B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Riverbridge Partners's Q2 2017 filing shows 10 new, 12 increased, 104 reduced and 6 closed positions. Its largest new stake was Evolent Health: 2,322,594 shares worth $58.9M. The largest sale was ZELTIQ Aesthetics, Inc., an estimated $70.1M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Industrials and Healthcare.

  • Riverbridge Partners's largest Q2 2017 buy was Evolent Health: 2,322,594 shares worth $58.9M.
  • Riverbridge Partners added most to Verisk Analytics in Q2 2017, an estimated $23.2M increase.
  • Riverbridge Partners's biggest Q2 2017 reduction was Cognex, cutting an estimated $62.5M.
  • Riverbridge Partners fully exited ZELTIQ Aesthetics, Inc. in Q2 2017, selling an estimated $70.1M.
  • Riverbridge Partners's ten largest holdings make up 29% of its $5.23B portfolio in Q2 2017.
  • Riverbridge Partners opened 10 new positions and closed 6 in Q2 2017.
  • Riverbridge Partners's portfolio value rose 5% quarter-over-quarter to $5.23B.

Based on Riverbridge Partners's 13F filing for Q2 2017, filed 24 Jul 2017.